Zobrazeno 1 - 10
of 57
pro vyhledávání: '"A. Seroutou"'
Publikováno v:
BMC medical research methodology, 2021
Phase I dose-escalation trials constitute the first step in investigating the safety of potentially promising drugs in humans. Conventional methods for phase I dose-escalation trials are based on a single treatment schedule only. More recently, howev
Externí odkaz:
http://arxiv.org/abs/1811.09433
Publikováno v:
BMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background Conventional methods for phase I dose-escalation trials in oncology are based on a single treatment schedule only. More recently, however, multiple schedules are more frequently investigated in the same trial. Methods Here, we con
Externí odkaz:
https://doaj.org/article/3ba3de22ca8b4b09b849def7df152e0f
Autor:
Kerry Lynn Reynolds, Philippe L. Bedard, Se-Hoon Lee, Chia-Chi Lin, Josep Tabernero, Maria Alsina, Ezra Cohen, José Baselga, George Blumenschein, Donna M. Graham, Ignacio Garrido-Laguna, Dejan Juric, Sunil Sharma, Ravi Salgia, Abdelkader Seroutou, Xianbin Tian, Rose Fernandez, Alex Morozov, Qing Sheng, Thiruvamoor Ramkumar, Angela Zubel, Yung-Jue Bang
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017)
Abstract Background Human epidermal growth factor receptor 3 (HER3) is important in maintaining epidermal growth factor receptor-driven cancers and mediating resistance to targeted therapy. A phase I study of anti-HER3 monoclonal antibody LJM716 was
Externí odkaz:
https://doaj.org/article/6a99ce44899c48d0b69a8d0fc67f0c5c
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
(A) Average body weight of mice treated with each BRAF inhibitor in the experiment depicted in Figure 1C; (B) Encorafenib plasma exposure in mice following the last dose from the experiment depicted in Figure 1C. To estimate daily exposure on the BID
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e582a2e6528fa79c1c59d17f45ea091
https://doi.org/10.1158/1078-0432.22467995
https://doi.org/10.1158/1078-0432.22467995
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis. We evaluated encorafenib in a phase I study in patients with BRAFi treatment-naïve and pretreated BRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d33fd78b0f824a6d521ad7699f44e3c
https://doi.org/10.1158/1078-0432.c.6526808
https://doi.org/10.1158/1078-0432.c.6526808
Autor:
Reinhard Dummer, Tim Demuth, Laure Moutouh-de Parseval, Darrin D. Stuart, Giordano Caponigro, Vassilios Aslanis, Abdelkader Seroutou, Daniela Michel, Carlos Gomez-Roca, Manuel Hidalgo, Matteo S. Carlino, Richard F. Kefford, Ana Arance, Ryan Sullivan, Yasuhide Yamada, Amit Mahipal, Ragini Kudchakar, Grant A. McArthur, Marta Nyakas, Caroline Robert, Jean-Pierre Delord
Biochemical and cellular potency of encorafenib, dabrafenib, and vemurafenib in biochemical and cell-based assays. Purified BRAF V600E kinase domain was used in the biochemical experiments, using kinase-dead MEK1 as a substrate and a phosphorylated M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e51957f9f54ec77b6c8a756ef60a095
https://doi.org/10.1158/1078-0432.22467989
https://doi.org/10.1158/1078-0432.22467989
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nicole Gerwin, Celeste Scotti, Christine Halleux, Mara Fornaro, Jimmy Elliott, Yunyu Zhang, Kristen Johnson, Jian Shi, Sandra Walter, Yufei Li, Carsten Jacobi, Nelly Laplanche, Magali Belaud, Jochen Paul, Gustavo Glowacki, Thomas Peters, Keith A. Wharton, Igor Vostiar, Florine Polus, Ina Kramer, Sabine Guth, Abdelkader Seroutou, Subhajit Choudhury, Didier Laurent, Joseph Gimbel, Jörg Goldhahn, Matthias Schieker, Sophie Brachat, Ronenn Roubenoff, Michaela Kneissel
Publikováno v:
Nature medicine. 28(12)
Osteoarthritis (OA) is a common, debilitating, chronic disease with no disease-modifying drug approved to date. We discovered LNA043—a derivative of angiopoietin-like 3 (ANGPTL3)—as a potent chondrogenesis inducer using a phenotypic screen with h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f078387a12de39fc637fdf38fb32ac7
https://pubmed.ncbi.nlm.nih.gov/36456835
https://pubmed.ncbi.nlm.nih.gov/36456835
Publikováno v:
BMC Medical Research Methodology, Vol 21, Iss 1, Pp 1-14 (2021)
BMC Medical Research Methodology
BMC Medical Research Methodology
Background Conventional methods for phase I dose-escalation trials in oncology are based on a single treatment schedule only. More recently, however, multiple schedules are more frequently investigated in the same trial. Methods Here, we consider seq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1c7007fe74835ab7cc26fdb2a083864f
http://resolver.sub.uni-goettingen.de/purl?gs-1/17760
http://resolver.sub.uni-goettingen.de/purl?gs-1/17760
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.